Abeona Therapeutics

Positives: monetizing the PRV for $155 million at launch was disciplined and non‑dilutive; building in‑house cGMP capacity should reinforce quality, reduce long‑term COGS and serve as a strategic asset; selective out‑licensing (e.g., AAV204 to Beacon) and sublicense revenues (Taysha milestone) diversify cash inflows.

Offsets: meaningful stock‑based compensation (~$10.8 million in 2025) and ATM usage in 2024–2025 increased share count; Avenue debt carries double‑digit cost and warrants; and the business remains dependent on near‑term operating leverage to avoid further equity raises.

Overall, capital deployment has been pragmatic for a pre‑revenue‑to‑commercial transition but remains execution‑sensitive.